John Allan

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Andrew D. Zelenetz, MD, PhD, is the Attending Physician, Lymphoma Service, Department of Medicine at Memorial Sloan Kettering Cancer Center. He was the Medical Director, Quality Informatics 2016-12/31/23. Prior to that, he held the positions of Vice-Chair - Medical Informatics January 2013 - May 2016 & Chief of Lymphoma Service, Division of Hematology/Oncology at MSK from 1994 to December 2012. He also is Professor of Medicine at Weill Medical College of Cornell University.

Dr. Zelenetz received his Bachelor of Arts degree from Harvard College, doctorate of philosophy from Harvard University's Graduate School of Arts & Sciences Division of Medical Sciences, and medical degree from Harvard Medical School. Completed both his internship and residency in internal medicine at Stanford University MC, where he completed clinical and research fellowships in oncology.

He has helped develop a number of agents now approved to treat lymphoma -- including 131I-tosituomab/tositumomab, bortezomib, pralatrexate, idelalisisb, obinutuzumab, zanubrutinib, and venetoclax. Through clinical studies, he is evaluating benefits of novel combinations of agents. He has published more than 200 papers on lymphoma research in journals

Dr. Zelenetz is a member of the ASH, ASCO, and the American College of Physicians. He participates in various committees: member of the Alliance Lymphoma Core Committee; is the immediate past chair of the SAB of the LRF. He has been the recipient of the MSKCC Fellowship Teaching Excellence Award multiple times, and he received the NCCN Rodger Winn Award from in 2012.

Dr. Zelenetz is co-Chair of the NCCN B cell Guidelines Committee.

Richard R. Furman, MD is the Morton Coleman, M.D. Distinguished Professor of Medicine and director of CLL Research Center at Weill Cornell. He attended medical school at the Mount Sinai School of Medicine followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania. He subsequently completed fellowship in Hematology and Oncology at Weill Cornell Medical College. After fellowship, Dr. Furman performed laboratory based research on cognate and non-cognate immune interactions in CLL, focusing on NF-kappaB and B cell differentiation. Dr. Furman subsequently left the laboratory to pursue clinical research and patient care with an interest on the development of non-chemotherapeutic approaches for the treatment of CLL and lymphomas. He initially focused on thalidomide and lenalidomide, before working on novel monoclonal antibodies, BCR antagonists, and other small molecule inhibitors. Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, and venetoclax, as well as understanding and treating mechansims of resistance.

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She competed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College. Dr. Mulvey has also completed a Master's Degree in Clinical Investigation and Translational Research at the Weill Cornell School of Graduate Sciences.

Dr. Mulvey is a member of the Weill Cornell Lymphoma Program where she specializes in treating patients with lymphoma and chronic lymphocytic leukemia (CLL) and is an active investigator in several clinical trials. Her research is centered on B cell lymphomas and CLL. Dr. Mulvey is focused on the study and manipulation of the interaction between the body’s own immune system and cancerous cells. She also has a special interest in health realted quality of life and the use of patient reported outcomes in clinical trials, and has received honors from the Lymphoma Research Foundation (LRF) and the NIH.

Javier Pinilla-Ibarz, MD, PhD, is physician scientist Senior Member, Head of Lymphoma Section and Director of Immunotherapy in the Malignant Hematology Department at H. Lee Moffitt Cancer Center in Tampa, Florida. Dr. Pinilla-Ibarz is also a Professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida.

Dr. Pinilla-Ibarz has been leading the chronic leukemia program at Moffitt since 2006, and its principal interests in the clinic are patients with myeloid and lymphoid chronic leukemia. Dr. Pinilla-Ibarz has participated in multiple clinical trials involving several kinase inhibitors, many of them now FDA approved.
He has been involved in developing new immunotherapeutic approaches in malignant hematology with special emphasis of restoring the impaired immune response of patients with chronic leukemias. He has participated in several clinical trials of peptide and cellular vaccines in different hematological disorders. He has been involved in the development of a Wilms tumor 1 vaccine for leukemias and other solid tumor now in phase III trial across the world. His laboratory is interested in epigenetic immunoregulation in lymphoid malignancies such as B and T cell lymphomas through the use of epigenetic modifiers such as histone deacetylase inhibitors and hypomethylating agents. Other research focuses are on the interaction of kinase inhibitors with the immune system and how to use these drugs to improve current immune therapeutics approaches.

Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center.

After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College.
Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous co-stimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bi-specific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells).

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.

Asher A. Chanan-Khan, M.D. is dedicated to advancing and discovering treatments for patients with chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, and multiple myeloma. For over two decade, Professor Chanan-Khan has been engaged in the development of novel therapeutics through laboratory and clinical research. His expertise is in preclinical target validation and drug evaluation directed towards early phase clinical trials. Dr. Chanan-Khan has sserved as the principal investigator or co-principal investigator on numerous clinical trials for patients with these disorders authoring over 200 publications. Administratively, Dr. Chanan-Khan completed his tenure as the Chair of Hematology & Oncology at Mayo Clinic in Florida, member of the Florida Cancer Control & Research Advisory Council (CCRAB) and past member of the NCCN CLL and Myeloma Guideline committees. He is an active member of ASH and ASCO. Dr. Chanan-Khan is an animal conservationist volunteering as a member of the Board on Jacksonville Zoo and a passionate supporter of the non-profit organisation "Open Hands Global" (https://www.openhandsglobal.org) committed to fighting bonded slavery in SouthEast Asia.

Dr. Justin Taylor is the Pap Corp Endowed Professor in Leukemia and a physician-scientist in the Division of Hematology and Department of Medicine at the University of Miami Miller School of Medicine. He serves as the Translational Leader for the Leukemia Group and is a full member of the Sylvester Comprehensive Cancer Center. Before joining Sylvester in 2020, he completed his medical training at Brigham & Women’s Hospital, part of Harvard Medical School, and his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. In addition to seeing patients, he performs laboratory research and has received several awards, including the Stanley J. Glaser Award and the Schally Research Award from the Department of Medicine and the Outstanding Basic/Translational Researcher of the Year from Sylvester Comprehensive Cancer Center. Dr. Taylor was recently elected to the American Society of Clinical Investigation. His research focuses on understanding and overcoming resistance to targeted therapies in hematologic cancers. His group published on BTK mutations causing resistance to covalent and non-covalent BTK inhibitors and classified them based on kinase activity into kinase proficient and kinase impaired. They went on to show that both types of mutations are susceptible to BTK degrader therapies in clinical trials. Recent work is focused on resistance mechanisms to BTK degraders.

Dr. Allan is an Associate Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. Dr. Allan completed his undergraduate education at the University of Missouri-Columbia and graduated with a BS in both Biochemistry and Finance. He subsequently obtained his medical degree from Saint Louis University.
Dr. Allan moved to New York in 2009 to train at New York-Presbyterian Hospital, Weill Cornell Medical Campus, where he also completed his residency and hematology and medical oncology fellowship.
Upon completion of training Dr. Allan joined the lymphoma faculty in the Division of Hematology and Oncology. Dr. Allan treats all lymphoid malignancies and has a particular interest in improving therapies for patients with CLL and Richter’s Syndrome, which is the focus of his research.